SABCS 2021 | KEYNOTE-522: EFS sensitivity & subgroup analyses

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, updates us on the findings of an event-free survival (EFS) sensitivity and subgroup analyses from the KEYNOTE-522 study (NCT03036488), a Phase III trial evaluating neoadjuvant pembrolizumab plus chemotherapy vs. placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo in early-stage triple-negative breast cancer (TNBC). EFS sensitivity analyses show a robust treatment benefit of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for previously untreated non-metastatic TNBC. This benefit was generally consistent across a broad selection of patient subgroups. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.